News Another 340B lawsuit gets underway, in Illinois Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
News AbbVie tries a new approach in 340B programme battle AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
News US court says pharma giants must face False Claims suit An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.
News Court blocks HHS' 340B rebate programme pilot Hospitals that challenged a US pilot of a new rebate model for medicines provided to low-income people have won another legal victory.
News Judge blocks HHS' 340B rebate pilot at 11th hour A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.
Market Access Smoothing a contract pathway through uncertainty: In convers... Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.
News After failure in sickle cell, Fulcrum merges with Slate Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
